Université Côte d'Azur, Inserm, CNRS, Institut de Pharmacologie Moléculaire et Cellulaire, 660 route des lucioles, 06560 Valbonne, France.
Institut Curie, Université PSL, Sorbonne Université, CNRS UMR168, Laboratoire Physico-Chimie Curie, 75005 Paris, France.
Dev Cell. 2023 Jan 23;58(2):121-138.e9. doi: 10.1016/j.devcel.2022.12.010.
Membrane contact sites (MCSs) are heterogeneous in shape, composition, and dynamics. Despite this diversity, VAP proteins act as receptors for multiple FFAT motif-containing proteins and drive the formation of most MCSs that involve the endoplasmic reticulum (ER). Although the VAP-FFAT interaction is well characterized, no model explains how VAP adapts to its partners in various MCSs. We report that VAP-A localization to different MCSs depends on its intrinsically disordered regions (IDRs) in human cells. VAP-A interaction with PTPIP51 and VPS13A at ER-mitochondria MCS conditions mitochondria fusion by promoting lipid transfer and cardiolipin buildup. VAP-A also enables lipid exchange at ER-Golgi MCS by interacting with oxysterol-binding protein (OSBP) and CERT. However, removing IDRs from VAP-A restricts its distribution and function to ER-mitochondria MCS. Our data suggest that IDRs do not modulate VAP-A preference toward specific partners but do adjust their geometry to MCS organization and lifetime constraints. Thus, IDR-mediated VAP-A conformational flexibility ensures membrane tethering plasticity and efficiency.
膜接触位点(MCSs)在形状、组成和动力学方面具有异质性。尽管存在这种多样性,但 VAP 蛋白可作为多种含有 FFAT 基序的蛋白质的受体,并驱动涉及内质网(ER)的大多数 MCS 的形成。尽管 VAP-FFAT 相互作用已得到很好的描述,但尚无模型解释 VAP 如何适应各种 MCS 中的其伙伴。我们报告称,VAP-A 在不同 MCSs 中的定位取决于其在人细胞中的无规卷曲区域(IDRs)。在 ER-线粒体 MCS 条件下,VAP-A 与 PTPIP51 和 VPS13A 的相互作用通过促进脂质转移和心磷脂积累促进线粒体融合。VAP-A 还通过与甾醇结合蛋白(OSBP)和 CERT 相互作用,在 ER-高尔基体 MCS 中实现脂质交换。然而,从 VAP-A 中去除 IDR 会限制其分布和功能仅限于 ER-线粒体 MCS。我们的数据表明,IDR 不会调节 VAP-A 对特定伙伴的偏好,但会根据 MCS 组织和寿命限制调整其几何形状。因此,IDR 介导的 VAP-A 构象灵活性确保了膜系留的可塑性和效率。